Clinical Trial Islet Transplantation


(livelife8888) #1

I put this on here because I  think people should stay in touch with what is going on in the T1 world

lets hope it works soon!!!! 

The goal of islet transplantation is to give back only the cells necessary for blood sugar control. Instead of major surgery, the procedure is performed in a radiology suite, and takes approximately 20 – 30 minutes.  

The objectives of clinical islet transplantation are to:

  • Determine whether the natural history of the micro-vascular, macro- vascular and neuropathic complications are altered following successful transplantation of islet cells. 
  • Assess long-term function of successful islet cell transplants in patients with type 1 diabetes. 
  • Establish an improvement in the glycemic control and/or the reversal of insulin dependency in patients with unstable type 1 diabetes.   


Though progress has been substantial, islet transplantation remains an experimental procedure. The DRI’s Clinical Islet Transplant team continues to develop and test new protocols to improve islet transplantation, and is actively involved in screening individuals for participation. 

Current Clinical Studies 

 

1. Steroid-Free/Calcineurin-Free Trial in Islet Cell Transplantation Utilizing Campath-1H as Induction Therapy

2. Islet Cell Transplantation Alone and CD34+ Enriched Donor Bone Marrow Cell Infusion in Patients with Type 1 Diabetes Mellitus; Steroid-Free Regimen Using Campath 1H as Induction Therapy  


3. Islet Cell Transplantation Alone in Patients with Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression*   

4. Islet After Kidney Transplant*  


5. Strategies to Improve Long Term Islet Graft Survival.


*The drug, Exenatide will be initiated at time of islet infusion to evaluate its ability to enhance islet engraftment and long term function through its anti-apoptotic (cell protective) properties.

Also, participants that achieved insulin independence after islet transplantation but again require insulin, will be offered the opportunity to test the ability of 
Exenatide to increase islet mass and potentially,
restore insulin independence.  

Strict inclusion criteria must be met to participate in this experimental procedure.

If you would like to receive information about the DRI's clinical islet transplant trials, please
download the form by clicking here.

For information about federally and privately supported clinical trials being conducted at other centers,
click here. The information provided  should be used in conjunction with advice from health care professionals.

 

The DRI collaborates with other researchers through the Clinical Islet Transplantation Consortium, a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.  Click here for a CITC brochure.

 

The DRI collaborates with other researchers through the Clinical Islet Transplantation Consortium, a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.  Click here for a CITC brochure.

The goal of islet transplantation is to give back only the cells necessary for blood sugar control. Instead of major surgery, the procedure is performed in a radiology suite, and takes approximately 20 – 30 minutes.  

The objectives of clinical islet transplantation are to:

  • Determine whether the natural history of the micro-vascular, macro- vascular and neuropathic complications are altered following successful transplantation of islet cells. 
  • Assess long-term function of successful islet cell transplants in patients with type 1 diabetes. 
  • Establish an improvement in the glycemic control and/or the reversal of insulin dependency in patients with unstable type 1 diabetes.   


Though progress has been substantial, islet transplantation remains an experimental procedure. The DRI’s Clinical Islet Transplant team continues to develop and test new protocols to improve islet transplantation, and is actively involved in screening individuals for participation. 

Current Clinical Studies 

 

1. Steroid-Free/Calcineurin-Free Trial in Islet Cell Transplantation Utilizing Campath-1H as Induction Therapy

2. Islet Cell Transplantation Alone and CD34+ Enriched Donor Bone Marrow Cell Infusion in Patients with Type 1 Diabetes Mellitus; Steroid-Free Regimen Using Campath 1H as Induction Therapy  


3. Islet Cell Transplantation Alone in Patients with Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression*   

4. Islet After Kidney Transplant*  


5. Strategies to Improve Long Term Islet Graft Survival.


*The drug, Exenatide will be initiated at time of islet infusion to evaluate its ability to enhance islet engraftment and long term function through its anti-apoptotic (cell protective) properties.

Also, participants that achieved insulin independence after islet transplantation but again require insulin, will be offered the opportunity to test the ability of 
Exenatide to increase islet mass and potentially,
restore insulin independence.  

Strict inclusion criteria must be met to participate in this experimental procedure.

If you would like to receive information about the DRI's clinical islet transplant trials, please
download the form by clicking here.

For information about federally and privately supported clinical trials being conducted at other centers,
click here. The information provided  should be used in conjunction with advice from health care professionals.

 

 

The DRI collaborates with other researchers through the Clinical Islet Transplantation Consortium, a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.  Click here for a CITC brochure